Abstract
Worlwide prevalence of diabetes mellitus is ~347 million. There are two main types: type 1 diabetes mellitus (T1DM) or insulin-dependent DM affecting 10 % of individuals and type II diabetes mellitus (T2DM) affecting the rest, i.e., 90 %. Monitoring of diabetes mellitus is rapidly advancing toward fully automated glucose control systems such a personalized glucose advisory system (PGASystem) for management of DM. Adults with T1DM appear to be enthusiastic about using a PGASystem system for their diabetes management but also have significant concerns affecting their overall willingness to follow such a system’s advice because of the following concerns: (1) how the advice is generated; (2) relinquishing control to automated technology; and (3) inadequate personalization of the system (Shepard et al. 2012).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ananthakrishnan AN. Personalizing therapy for inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol. 2013;7:549–58.
Camilleri M. Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications. Neurogastroenterol Motil. 2007;19(s2):40–5.
Ceriello A, Barkai L, Christiansen JS, et al. Diabetes as a case study of chronic disease management with a personalized approach: the role of a structured feedback loop. Diabetes Res Clin Pract. 2012;98:5–10.
Cobb JP, Mindrinos MN, Miller-Graziano C, et al. Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A. 2005;102:4801–6.
Emami-Riedmaier A, Schaeffeler E, Nies AT, et al. Stratified medicine for the use of anti-diabetic medication in treatment of type 2 diabetes and cancer: where do we go from here? J Intern Med. 2014. doi:10.1111/joim.12330.
Levy-Nissenbaum E, Bar-Natan M, Frydman M, Pras E. Confirmation of the association between male pattern baldness and the androgen receptor gene. Eur J Dermatol. 2005;15:339–40.
Mosli MH, Sandborn WJ, Kim RB, et al. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014;109:994–1004.
Nappi RE, Domoney C. Pharmacogenomics and sexuality: a vision. Climacteric. 2013;16(1):25–30.
Schmidt MA, Goodwin TJ. Personalized medicine in human space flight: using omics based analyses to develop individualized countermeasures that enhance astronaut safety and performance. Metabolomics. 2013;9:1134–56.
Shepard JA, Gonder-Frederick L, Vajda K, Kovatchev B. Patient perspectives on personalized glucose advisory systems for type 1 diabetes management. Diabetes Technol Ther. 2012;14:858–61.
Spiegel AM, Hawkins M. ‘Personalized medicine’ to identify genetic risks for type 2 diabetes and focus prevention: can it fulfill its promise? Health Aff (Millwood). 2012;31:43–9.
Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16:378.
Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis – where do we go from here? NEJM. 2012;366:2048–51.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Jain, K.K. (2015). Personalized Approaches to Miscellaneous Problems in Healthcare. In: Textbook of Personalized Medicine. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2553-7_18
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2553-7_18
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-2552-0
Online ISBN: 978-1-4939-2553-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)